JP2025508316A5 - - Google Patents

Info

Publication number
JP2025508316A5
JP2025508316A5 JP2024543215A JP2024543215A JP2025508316A5 JP 2025508316 A5 JP2025508316 A5 JP 2025508316A5 JP 2024543215 A JP2024543215 A JP 2024543215A JP 2024543215 A JP2024543215 A JP 2024543215A JP 2025508316 A5 JP2025508316 A5 JP 2025508316A5
Authority
JP
Japan
Prior art keywords
peptide linker
fragment
multispecific antibody
antibody according
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508316A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/061051 external-priority patent/WO2023141611A2/en
Publication of JP2025508316A publication Critical patent/JP2025508316A/ja
Publication of JP2025508316A5 publication Critical patent/JP2025508316A5/ja
Pending legal-status Critical Current

Links

JP2024543215A 2022-01-21 2023-01-20 アビディティ受容体架橋及び免疫調節における使用における多重特異性抗体 Pending JP2025508316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/073220 2022-01-21
CN2022073220 2022-01-21
PCT/US2023/061051 WO2023141611A2 (en) 2022-01-21 2023-01-20 Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation

Publications (2)

Publication Number Publication Date
JP2025508316A JP2025508316A (ja) 2025-03-26
JP2025508316A5 true JP2025508316A5 (cg-RX-API-DMAC7.html) 2026-01-27

Family

ID=87349191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543215A Pending JP2025508316A (ja) 2022-01-21 2023-01-20 アビディティ受容体架橋及び免疫調節における使用における多重特異性抗体

Country Status (5)

Country Link
US (1) US20250388669A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466020A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508316A (cg-RX-API-DMAC7.html)
CN (1) CN119053342A (cg-RX-API-DMAC7.html)
WO (1) WO2023141611A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN122138978A (zh) * 2023-07-26 2026-06-02 礼进生物医药控股有限公司 整合双重免疫调节部分的多特异性抗体及其在免疫疗法中的用途
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
CN122070305A (zh) * 2023-09-21 2026-05-19 艾科联生物科技(上海)有限公司 多特异性抗体及其用途
CN119912577A (zh) * 2023-10-31 2025-05-02 北京智仁美博生物科技有限公司 结合hla-a24/prame复合体的多种抗体及其用途
TW202545992A (zh) * 2024-01-23 2025-12-01 中國大陸商上海藥明生物技術有限公司 靶向cd3、cd19及cd20之多特異性抗體及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013027224A8 (pt) * 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
WO2013070615A1 (en) * 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
US20170183397A1 (en) * 2014-05-05 2017-06-29 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
MX2020011844A (es) * 2018-05-08 2021-04-13 Amgen Inc Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.
IL325918A (en) * 2018-07-31 2026-03-01 Daiichi Sankyo Co Ltd Antibody-drug conjugates for use in the treatment of metastatic brain tumor
CN121975011A (zh) * 2019-09-27 2026-05-05 北京烁星生物医药科技有限公司 单特异性和多特异性抗体

Similar Documents

Publication Publication Date Title
JP2024532485A5 (cg-RX-API-DMAC7.html)
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2021042257A5 (cg-RX-API-DMAC7.html)
JP2021098732A5 (cg-RX-API-DMAC7.html)
JP2025078629A5 (cg-RX-API-DMAC7.html)
JP2022541435A5 (cg-RX-API-DMAC7.html)
JP2021520812A5 (cg-RX-API-DMAC7.html)
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JP2020516287A5 (cg-RX-API-DMAC7.html)
JP7549961B2 (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
JP2022514693A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
JP2019525738A5 (cg-RX-API-DMAC7.html)
JP2023509212A5 (cg-RX-API-DMAC7.html)
IL276903B1 (en) Bispecific egfr/cd16 antigen-binding protein
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2023507729A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
JP2017522891A5 (cg-RX-API-DMAC7.html)
JP2024508672A5 (cg-RX-API-DMAC7.html)
JP2022504826A5 (cg-RX-API-DMAC7.html)
JP2023511376A5 (cg-RX-API-DMAC7.html)
JP2023159379A (ja) Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途
CN115066274A (zh) 三价结合分子
JP2025508882A5 (cg-RX-API-DMAC7.html)